Given that Egfl6 enhanced the expression of PD-L1 on tumor-infiltrating myeloid cells (Figure 3C) and inhibited the response to ICI therapy (Figure 4, A and B), we reasoned that targeting tumor-derived Egfl6 might reverse the immunosuppressive TME and restore the efficacy of a-PD-L1 treatment in a 2F8c tumor model. Here, EGFL6 is linked to neoplasm.